Genetic Analysis AS 2025 Annual Report
The report outlines Genetic Analysis AS's commercial and financial performance for the fiscal year 2025. The company achieved record sales of NOK 16.7 million, driven by expanding its presence in the U.S. and launching the GA-map® Dysbiosis Test in China. Key milestones include completing the biomarker panel for the Inflammatory Bowel Disease (IBD) project and launching the GA-map® MHI GutHealth test. Genetic Analysis AS also improved its net loss to NOK 11.4 million and increased its total assets to NOK 52.4 million. The company remains committed to ethical business practices, anti-corruption, and providing a safe, inclusive working environment.
Company: Genetic Analysis AS
Sector: Professional & technical services
Country: Norway
Year: 2025
Type: Annual Report
Pages: 64
Back to company
Genetic Analysis AS
Annual Report
The report outlines Genetic Analysis AS's commercial and financial performance for the fiscal year 2025. The company achieved record sales of NOK 16.7 million, driven by expanding its presence in the U.S. and launching the GA-map® Dysbiosis Test in China. Key milestones include completing the biomarker panel for the Inflammatory Bowel Disease (IBD) project and launching the GA-map® MHI GutHealth test. Genetic Analysis AS also improved its net loss to NOK 11.4 million and increased its total assets to NOK 52.4 million. The company remains committed to ethical business practices, anti-corruption, and providing a safe, inclusive working environment.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report
Language
English
Pages
File Size
Standards & Assurance
No data available
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees